AN2 Therapeutics, Inc. (ANTX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-09

Key Insights

AN2 Therapeutics has entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to issue and sell up to $80 million in common stock at its discretion.
The company has terminated its previous sales agreement with Cowen and Company, LLC, which had allowed it to sell $20 million in shares.
This new agreement provides AN2 Therapeutics with additional financial flexibility and access to capital markets to fund its operations and development efforts.

Want the newest filings?

This analysis covers the filing from 2026-04-09. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-20

The company approved a stock option repricing program that reduces the exercise price of all outstanding stock options to $3.91 per share, the closing price on the repricing date. This should provide added incentives to retain and motivate plan participants without significant stock dilution or cash expenditures.
The repricing program includes a 'Premium End Date' where holders must pay the original exercise price if the options are exercised prior to September 19, 2027, a change in control, or the holder's death/disability. This helps align participants' interests with long-term shareholder value creation.
The company's named executive officers hold a significant number of the eligible options, with exercise prices ranging from $6.60 to $17.88 per share. The repricing and retention program may help secure their continued leadership during this critical period.

Filed: 2026-03-10

AN2 Therapeutics, Inc. has entered into a $40 million private placement with certain investors, providing the company with additional capital to fund its operations.
The company issued 8,245,611 shares of common stock and 5,789,493 pre-funded warrants as part of the private placement, with the warrants exercisable at a price of $0.00001 per share.
The company has agreed to file a resale registration statement with the SEC within 30 days of the closing of the private placement to register the shares issued and the shares underlying the pre-funded warrants.

Filed: 2026-01-29

AN2 Therapeutics has appointed Sarah Williams as its new Vice President, Controller and Principal Accounting Officer, indicating a change in the company's leadership team.
The company has entered into an Amended and Restated Employment Letter Agreement with Lucy Day, the current Chief Financial Officer and Principal Financial Officer, which includes a reduction in her annual base salary effective April 1, 2026.
The company is undertaking cost-saving efforts, as evidenced by the reduction in Lucy Day's compensation, which could have implications for the company's financial performance and operations.

Other reports for AN2 Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.